If everything goes according to the revised plan, Modern (NASDAQ: MRNA) you will have many more doses of your coronavirus vaccine on the market than previously anticipated. The company announced Monday that it is raising its base case estimate for global mRNA-1273 production in 2021 to 600 million doses from the previous forecast of 500 million.
Ideally, it will produce up to 1 billion a year. It is currently adding personnel to achieve this capability.
Among other factors, Moderna is basing its new estimate on initial launches of the coronavirus vaccine in North America.
Image source: Getty Images.
“Our effectiveness in providing early delivery to the governments of the United States and Canada and our ability to increase baseline production estimates for 2021 are signs that our expansion of mRNA vaccine production is successful,” said the chief. technical operations and quality officer, Juan Andres.
MRNA-1273 is the second coronavirus vaccine to receive emergency use authorization from the U.S. Food and Drug Administration. It’s the first, Pfizer and BioNTechBNT162b2 da, are currently being distributed and administered in the country.
In an attempt to deal with a coronavirus outbreak that is still getting worse, the US government signed a contract with Moderna for 200 million doses of mRNA-1273. The company believes it will have 100 million doses available in the country by the end of this quarter. Some 18 million doses have been provided to the government so far.
The update of Moderna is good news for both the company and the country, as a wide vaccination is needed as soon as possible. The company’s shares rose just under 7% on Monday, against the 1.5% drop in S&P 500 index.